5.100EUR-2.30%Mkt Cap: 143.92M EURP/E: —Last update: 2026-05-19
Hyloris Pharmaceuticals SA engages in the research, development, and manufacture of pharmaceutical products to address medical needs. The company offers Maxigesic IV, a combination of paracetamol and ibuprofen used for p…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap143.92M EUR
Enterprise Value127.11M EUR
Revenue (TTM)8.83M EUR
Gross Profit6.83M EUR
Net Income (TTM)-6.33M EUR
Revenue/Share0.3210 EUR
Last Price5.100 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees55
CountryBE
SectorHealth Care
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)9.97
PEG—
EV/EBITDA-18.72
EV/Revenue14.39
P/S15.98
P/B5.28
EPS (TTM)-0.23
EPS (Forward)0.51
52W Range
4.51015% of range8.400
52W High8.400 EUR
52W Low4.510 EUR
Profitability
Gross Margin94.74%
Oper. Margin-76.19%
EBITDA Margin-76.87%
Profit Margin-87.89%
ROE-23.92%
ROA-18.99%
Growth
Revenue Growth7.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.99M EUR
CapEx (TTM)629.00K EUR
FCF Margin-73.88%
FCF Yield-4.53%
Net Debt-12.66M EUR
Net Debt/EBITDA1.86
Balance Sheet
Debt/Equity0.06
Current Ratio3.89
Quick Ratio3.85
Book Value/Sh0.9550 EUR
Cash/Share0.5140 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)13.57 EUR
Target Range6.000 EUR – 20.40 EUR
# Analysts3
Ownership
Shares Out.28.00M
Float11.36M
Insiders58.14%
Institutions0.01%
Technical
SMA 505.344 (-4.6%)
SMA 2006.184 (-17.5%)
Beta0.65
S&P 52W Chg27.23%
Avg Vol (30d)5.84K
Avg Vol (10d)2.67K
Technical Indicators
RSI (14)46.6
MACD-0.0808
MACD Signal-0.1024
MACD Hist.+0.0216
BB Upper5.748 EUR
BB Middle5.303 EUR
BB Lower4.859 EUR
BB Width16.75%
ATR (14)0.2221 EUR
Vol Ratio (20d)0.13x